31181-84-7

Usage

Uses

Used in Organic Synthesis:
(5-TRIFLUOROMETHYL-PYRIDIN-2-YL) METHANOL is used as a synthetic intermediate for the preparation of various organic compounds. Its unique structure allows for versatile reactions, making it a valuable component in the synthesis of complex organic molecules.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (5-TRIFLUOROMETHYL-PYRIDIN-2-YL) METHANOL is utilized as a building block for the development of pharmaceuticals. Its incorporation into drug molecules can potentially enhance their stability and efficacy, contributing to the advancement of new therapeutic agents.
Used in Agrochemicals:
(5-TRIFLUOROMETHYL-PYRIDIN-2-YL) METHANOL is also employed in the synthesis of agrochemicals, where its properties can improve the performance and stability of these compounds, thereby increasing their effectiveness in agricultural applications.
Used in Drug Discovery and Development:
(5-TRIFLUOROMETHYL-PYRIDIN-2-YL) METHANOL's trifluoromethyl group enhances its chemical and metabolic stability, making (5-TRIFLUOROMETHYL-PYRIDIN-2-YL) METHANOL a valuable tool in drug discovery and development. It can be used to improve the pharmacokinetic and pharmacodynamic properties of drug candidates, leading to more effective and safer medications.
Used in Biological Activity and Pharmacological Property Studies:
(5-TRIFLUOROMETHYL-PYRIDIN-2-YL) METHANOL has been studied for its potential biological activities and pharmacological properties, indicating its use in research aimed at understanding and exploiting its therapeutic potential for various medical conditions.

InChI:InChI=1/C7H6F3NO/c8-7(9,10)5-1-2-6(4-12)11-3-5/h1-3,12H,4H2

Upstream product

• 541-41-3 chloroformic acid ethyl ester 
• 80194-69-0 5-(trifluoromethyl)picolinic acid 
• 67-56-1 methanol 
• 100366-75-4 2‐iodo‐5‐(trifluoromethyl)pyridine 
• 50488-42-1 2-bromo-5-(trifluoromethyl)pyridine 
• 31224-82-5 5-(trifluoromethyl)pyridine-2-carbaldehyde 
• 124236-37-9 5-(trifluoromethyl)-pyridine-2-carboxylic acid methyl ester 

Downstream Products

• 128790-14-7 5-trifluoromethyl-pyridin-2-ylmethyl chloride 
• 1000773-62-5 2-(bromomethyl)-5-(trifluoromethyl)pyridine 
• 31224-82-5 5-(trifluoromethyl)pyridine-2-carbaldehyde 

Relevant academic research and scientific papers

Micromolecular compound with anti-inflammatory activity, and preparation method and drug application of micromolecular compound

The invention relates to the field of pharmaceutical chemistry, in particular to a compound (I) with anti-inflammatory activity and a preparation method. Pharmacodynamic tests prove that the compound has PDE-4 (phosphodiesterase-4) inhibition activity and can be used for treating and preventing inflammation related diseases.

HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME

The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof. The compound has a superior TRPA1 antagonist activity, and can provide a medicament useful for the prophylaxis or treatment of diseases involving TRPA1 antagonist and TRPA1.

NOVEL COMPOUNDS

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein L, X, Ra, Rb, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

1-(DIHYDRONAPHTHALENYL)PYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS

This invention relates to novel 1-(dihydronaphthalenyl)pyridones which are antagonists of the melanin-concentrating hormone receptor 1 (MCHR1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy

Synthesis and structure-activity relationships of varied ether linker analogues of the antitubercular drug (6 S)-2-nitro-6-{[4-(trifluoromethoxy) benzyl]oxy}-6,7-dihydro-5 H -imidazo[2,1- b ][1,3]oxazine (PA-824)

New analogues of antitubercular drug PA-824 were synthesized, featuring alternative side chain ether linkers of varying size and flexibility, seeking drug candidates with enhanced metabolic stability and high efficacy. Both α-methyl substitution and removal of the benzylic methylene were broadly tolerated in vitro, with a biaryl example of the latter class exhibiting an 8-fold better efficacy than the parent drug in a mouse model of acute Mycobacterium tuberculosis infection and negligible fragmentation to an alcohol metabolite in liver microsomes. Extended linkers (notably propenyloxy, propynyloxy, and pentynyloxy) provided greater potencies against replicating M. tb (monoaryl analogues), with propynyl ethers being most effective under anaerobic (nonreplicating) conditions (mono/biaryl analogues). For benzyloxybenzyl and biaryl derivatives, aerobic activity was maximal with the original (OCH2) linker. One propynyloxy-linked compound displayed an 89-fold higher efficacy than the parent drug in the acute model, and it was slightly superior to antitubercular drug OPC-67683 in a chronic infection model.

TRPV1 ANTAGONISTS

Compounds of formula (I) wherein R1, R2, R4, and W are defined in the description are TRPV 1 antagonists with CNS penetration. Compositions comprising such compounds and methods for treating conditions and disorders using